Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRd versus Rd in transplant-ineligible newly diagnosed multiple myeloma
2018-002068-15Phase 3Active
- Sponsor
- Fondazione EMN Italy
- Start
- Feb 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of carfilzomib, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Fondazione EMN Italy. Primary endpoints: minimal residual disease and progression-free survival. Started Feb 2019; status: active.
02
Drugs
carfilzomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2018-002068-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002068-15.